Skip to content

Independent digital newspaper of Italian-speaking Switzerland

Switzerland Health

Same drug, different insurer decisions

An RTS investigation reveals major differences between Swiss health insurers in approving reimbursement for cancer drugs not automatically covered. One patient only received the treatment he needed after a seven-month legal battle.

by Brenno 10 November 2026 3 min read

Pascal Rolle tells RTS his story: in 2023 he was diagnosed with an aggressive cancer of the blood and bone marrow, with a prognosis of less than a year to live. His oncologist twice asked his health insurer to cover Elzonris, a treatment that at the time was not on the list of drugs automatically reimbursed by basic insurance. The insurer refused. "I don't understand why there are people who decide who lives and who dies," Rolle says. The drug arrived only seven months later, with a lawyer's help. Today his cancer is in remission.

The case is not isolated. In oncology, one reimbursement request in three goes through an individual review by the health insurer, because it concerns drugs not automatically covered by basic insurance. Last year nearly 80,000 such requests were filed in Switzerland. A report by the Federal Office of Public Health, published in 2020, had already found major differences between insurers: some accept almost all requests, others reject more than half. The report did not, however, name the insurers.

After five years of legal proceedings and a ruling by the Federal Administrative Court, RTS obtained the original data insurers had been required to submit to the authorities. For the period 2017-2019, KPT, Assura and Groupe Mutuel accepted between 94% and 98% of requests. Sanitas, Atupri and Helsana, by contrast, ranged between 45% and 67%, against a national average of 76%.

prio.swiss, the insurers' umbrella organization, disputes the comparison, arguing that requests are not comparable from one insurer to another. Only Sanitas responded substantively, explaining that some cases counted as refusals were actually "therapeutic trials" with reimbursement conditional on results; recalculated this way, its acceptance rate would be around 80%.

The 2020 study had already ruled out accounting methods alone as the explanation for these gaps: using the same accounting rules as Sanitas, another insurer accepted 74% of requests in 2019, against 46% for Sanitas, a 28-point difference.

An identical fictitious dossier submitted to 16 major insurers received conflicting responses: three acceptances, four refusals, six proposals for a therapeutic trial, and three requests for further information. The study's authors attribute much of the disparity to the assessments of insurers' trust doctors, who often lack oncology specialization; their decisions remain poorly harmonized even though these doctors are paid by the insurers.

The same gaps for years

A 2024 reform made it mandatory for trust doctors at different insurers to share their assessments through a common tool, aiming to reduce disparities. prio.swiss says it is convinced that comparable cases would no longer show significant differences today. Only Atupri provided recent figures, which do not allow for a national comparison.

On the ground, the picture looks different. Solange Peters, head of oncology at Lausanne's university hospital (CHUV) and president of Oncosuisse, tells RTS she sees "the same winners and the same losers" among insurers, unchanged since 2020. "Insurers hold a power of life and death over patients," she says, describing herself as outraged by the inequalities she observes daily.

Two of her patients with the same pancreatic cancer and the same request recently received opposite decisions from their respective insurers. For a patient who is refused, the oncologist notes, options for appeal are almost nonexistent, because an appeal would take longer than the disease allows. A new assessment by the Federal Office of Public Health is expected in 2027.

Comments

No comments

There are no comments yet. Yours can be the first voice.

Leave a comment